glp-1 news today october 23 2025 KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and Use Looming GLP-1 drug patent expirations

TB-500, derived from the actin-binding domain of thymosin beta-4, is primarily studied for its effects on cytoskeletal dynamics, cellular migration, and angiogenesis in vitro, while BPC-157 has been investigated for its roles in fibroblast proliferation, growth factor receptor modulation, and nitric oxide system regulation

May 7, 2026 Articles, Blood Glucose Control, Blood Glucose Control, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,621 views What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it

SYNERGY-NASH is a randomized, double-blind, placebo-controlled phase 2 study comparing the efficacy and safety of tirzepatide in patients with non-alcoholic steatohepatitis (NASH)

The extracellular matrix surrounding hair follicles does more than provide structural support

If you already drank, do not panic

Unlock solutions with a local weight loss doctor to evaluate treatment plans suited to your needs